Shares of medical device company Penumbra (NYSE:PEN) fell 5.5% in the afternoon session after the company announced results ...

Penumbra, Inc. announced that the results of the STORM-PE randomized controlled trial showed that mechanical thrombectomy using ...

The study found that the use of the company’s computer-assisted vacuum thrombectomy (CAVT) system, a form of mechanical ...

LOS ANGELES--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced results of the company-sponsored PROMISE Study, demonstrating ...

The first of its kind RCT in acute intermediate-high-risk PE used a surrogate endpoint, but more data are on the horizon.

Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in ...

Launches Indigo® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical Officer Lightning™ 12 – Intelligent ...

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED ...

Offering a new option for physicians to address arterial thrombus removal, the Indigo System Lightning 7 combines the new Indigo System CAT™7 Aspiration Catheter with Lightning Intelligent Aspiration ...

The Penumbra 3D Trial successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy of the company's next-generation stent retriever, Penumbra 3D ...

Launches Indigo ® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical ...

BOSTON, Mass. - July 27, 2016 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that the Penumbra 3D Trial successfully met the primary trial endpoints, ...